Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human VEGFR2/KDR/Flk-1 Reference Antibody (MSB-0254, RUO) (HW338086)

Anti-Human VEGFR2/KDR/Flk-1 Reference Antibody (MSB-0254, RUO)
Anti-Human VEGFR2/KDR/Flk-1 Reference Antibody (MSB-0254, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHW338086
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG
ID de clonMSB-0254
Objetivo CD309, EC:2.7.10.1, FLK-1, FLK1, Fetal liver kinase 1, KDR, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, VEGFR-2, VEGFR2, Vascular endothelial growth factor receptor 2
Nivel de endotoxinas < 10 EU/mg
Pureza >95% as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso P35968
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosMSB-0254, MSB0254, MSB0254
Fondo

Vascular endothelial growth factor receptor 2 (CD309/VEGFR-2) is a ~151 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. CD309 is the therapeutic target of ramucirumab (Cyramza).

Referencias 1. Chen S, et al. Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma. Biochem Biophys Res Commun. 2022 May 14;604:158-164. [HW338086]
Nota For research use only. Not suitable for clinical or therapeutic use.
Imágenes
  • Anti-Human VEGFR2/KDR/Flk-1 Reference Antibody (MSB-0254, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Anti-Human CD309/KDR/VEGFR-2 (MSB-0254)

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores